Evidence map›Paper›PMID 35884544›Full record

ArticleCancers2022

Identification of Ubiquitin-Related Gene-Pair Signatures for Predicting Tumor Microenvironment Infiltration and Drug Sensitivity of Lung Adenocarcinoma.

Yumei Li, Lanfen An, Zhe Jia, Jingxia Li, E Zhou, Feng Wu, Zhengrong Yin, Wei Geng, Tingting Liao, Wenjing Xiao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yumei LiNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Lanfen AnDepartment of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Zhe JiaNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Jingxia LiNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
E ZhouNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Feng WuNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Zhengrong YinNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Wei GengNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Tingting LiaoNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Wenjing XiaoNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Jingjing DengNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Wenjuan ChenNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Minglei LiNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Yang JinNHC Key Laboratory of Pulmonary Diseases, Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Funding

National Natural Science Foundation of China 82070099
6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is a common pathological type of lung cancer worldwide, and new biomarkers are urgently required to guide more effective individualized therapy for patients. Ubiquitin-related genes (UbRGs) partially participate in the initiation and progression of lung cancer. In this study, we used ubiquitin-related gene pairs (UbRGPs) in tumor tissues to access the function of UbRGs in overall survival, immunocyte infiltration, and tumor mutation burden (TMB) of patients with LUAD from The Cancer Genome Atlas (TCGA) database. In addition, we constructed a prognostic signature based on six UbRGPs and evaluated its performance in an internal (TCGA testing set) and an external validation set (GSE13213). The prognostic signature revealed that risk scores were negatively correlated with the overall survival, immunocyte infiltration, and expression of immune checkpoint inhibitor-related genes and positively correlated with the TMB. Patients in the high-risk group showed higher sensitivity to partially targeted and chemotherapeutic drugs than those in the low-risk group. This study contributes to the understanding of the characteristics of UbRGPs in LUAD and provides guidance for effective immuno-, chemo-, and targeted therapy.

Indexed as

drug sensitivityimmune infiltrationlung adenocarcinomatumor microenvironmenttumor mutation burdenubiquitinubiquitin-related gene pair

Identifiers

PMID35884544
PMCPMC9317993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.